Case Reports

The Clinical Utility of Teledermatology in Triaging and Diagnosing Skin Malignancies: Case Series

Author and Disclosure Information

Practice Points

  • Teledermatology via store-and-forward technology has been demonstrated to be effective in assessing and triaging various cutaneous malignancies.
  • The use of teledermatology has increased because of the COVID-19 pandemic and may be useful for specific vulnerable populations.
  • When used appropriately, teledermatology may function as a useful resource to triage patients requiring in-person evaluation for the diagnosis of aggressive skin malignancies and may aid in reducing the time to diagnosis of various skin cancers.


 

References

With the increasing utilization of telemedicine since the COVID-19 pandemic, it is critical that clinicians have an appropriate understanding of the application of virtual care resources, including teledermatology. We present a case series of 3 patients to demonstrate the clinical utility of teledermatology in reducing the time to diagnosis of various rare and/or aggressive cutaneous malignancies, including Merkel cell carcinoma, malignant melanoma, and atypical fibroxanthoma. Cases were obtained from one large Midwestern medical center during the month of July 2021. Each case presented includes a description of the initial teledermatology presentation and reviews the clinical timeline from initial consultation submission to in-person clinic visit with lesion biopsy. This case series demonstrates real-world examples of how teledermatology can be utilized to expedite the care of specific vulnerable patient populations.

Teledermatology is a rapidly growing digital resource with specific utility in triaging patients to determine those requiring in-person evaluation for early and accurate detection of skin malignancies. Approximately one-third of teledermatology consultations result in face-to-face clinical encounters, with malignant neoplasms being the leading cause for biopsy.1,2 For specific populations, such as geriatric and immunocompromised patients, teledermatology may serve as a valuable tool, particularly in the wake of the COVID-19 pandemic. Furthermore, telemedicine may aid in addressing health disparities within the field of medicine and ultimately may improve access to care for vulnerable populations.3 Along with increasing access to specific subspecialty expertise, the use of teledermatology may reduce health care costs and improve the overall quality of care delivered to patients.4,5

We describe the clinical utility of teledermatology in triaging and diagnosing skin malignancies through a series of 3 cases obtained from digital image review at one large Midwestern medical center during the month of July 2021. Three unique cases with a final diagnosis of a rare or aggressive skin cancer were selected as examples, including a 75-year-old man with Merkle cell carcinoma, a 55-year-old man with aggressive pT3b malignant melanoma, and a 72-year-old man with an atypical fibroxanthoma. A clinical timeline of each case is presented, including the time intervals from initial image submission to image review, image submission to face-to-face clinical encounter, and image submission to final diagnosis. In all cases, the primary care provider submitted an order for teledermatology, and the teledermatology team obtained the images.

Case Series

Patient 1—Images of the right hand of a 75-year-old man with a medical history of basal cell carcinoma were submitted for teledermatology consultation utilizing store-and-forward image-capturing technology (day 1). The patient history provided with image submission indicated that the lesion had been present for 6 months and there were no associated symptoms. Clinical imaging demonstrated a pink-red pearly papule located on the proximal fourth digit of the dorsal aspect of the right hand (Figure 1). One day following the teledermatology request (day 2), the patient’s case was reviewed and triaged for an in-person visit. The patient was brought to clinic on day 34, and a biopsy was performed. On day 36, dermatopathology results indicated a diagnosis of Merkel cell carcinoma. On day 37, the patient was referred to surgical oncology, and on day 44, the patient underwent an initial surgical oncology visit with a plan for wide local excision of the right fourth digit with right axillary sentinel lymph node biopsy.

A lesion of concern on the fourth digit of the dorsal aspect of the right hand that initially was evaluated via teledermatology and later was diagnosed as Merkel cell carcinoma (patient 1).

FIGURE 1. A lesion of concern on the fourth digit of the dorsal aspect of the right hand that initially was evaluated via teledermatology and later was diagnosed as Merkel cell carcinoma (patient 1).

Patient 2—Images of the left flank of a 55-year-old man were submitted for teledermatology consultation via store-and-forward technology (day 1). A patient history provided with the image indicated that the lesion had been present for months to years and there were no associated symptoms, but the lesion recently had changed in color and size. Teledermatology images were reviewed on day 3 and demonstrated a 2- to 3-cm brown plaque on the left flank with color variegation and a prominent red papule protruding centrally (Figure 2). The patient was scheduled for an urgent in-person visit with biopsy. On day 6, the patient presented to clinic and an excision biopsy was performed. Dermatopathology was ordered with a RUSH indication, with results on day 7 revealing a pT3b malignant melanoma. An urgent consultation to surgical oncology was placed on the same day, and the patient underwent an initial surgical oncology visit on day 24 with a plan for wide local excision with left axillary and inguinal sentinel lymph node biopsy.

A lesion of concern on the left flank that initially was evaluated via teledermatology and later was diagnosed as a pT3b malignant melanoma (patient 2).

FIGURE 2. A lesion of concern on the left flank that initially was evaluated via teledermatology and later was diagnosed as a pT3b malignant melanoma (patient 2).

Patient 3—Images of the left ear of a 72-year-old man were submitted for teledermatology consultation utilizing review via store-and-forward technology (day 1). A patient history indicated that the lesion had been present for 3 months with associated bleeding. Image review demonstrated a solitary pearly pink papule located on the crura of the antihelix (Figure 3). Initial teledermatology consultation was reviewed on day 2 with notification of the need for in-person evaluation. The patient presented to clinic on day 33 for a biopsy, with dermatopathology results on day 36 consistent with an atypical fibroxanthoma. The patient was scheduled for Mohs micrographic surgery on day 37 and underwent surgical treatment on day 64.

A lesion of concern on the left ear that initially was evaluated via teledermatology and later was diagnosed as atypical fibroxanthoma (patient 3).

FIGURE 3. A lesion of concern on the left ear that initially was evaluated via teledermatology and later was diagnosed as atypical fibroxanthoma (patient 3).

Comment

Teledermatology consultations from all patients demonstrated adequate image quality to be able to evaluate the lesion of concern and yielded a request for in-person evaluation with possible biopsy (Table). In this case series, the average time interval from teledermatology consultation placement to teledermatology image report was 2 days (range, 1–3 days). The average time from teledermatology consultation placement to face-to-face encounter with biopsy was 24.3 days for the 3 cases presented in this series (range, 6–34 days). The initial surgical oncology visits took place an average of 34 days after the initial teledermatology consultation was placed for the 2 patients requiring referral (44 days for patient 1; 24 days for patient 2). For patient 3, Mohs micrographic surgery was required for treatment, which was scheduled by day 37 and subsequently performed on day 64.

Timeline of Teledermatology Visits for Lesions of Concern in 3 Patients

Pages

Recommended Reading

Less Than 50% of Accelerated Approvals Show Clinical Benefit
MDedge Dermatology
Repeat MCED Testing May ID Early-Stage and Unscreened Cancers
MDedge Dermatology
Circulating Tumor DNA Predicts Early Treatment Response in Patients With HER2-Positive Cancers
MDedge Dermatology
Consider Skin Cancer, Infection Risks in Solid Organ Transplant Recipients
MDedge Dermatology
Oncologists Voice Ethical Concerns Over AI in Cancer Care
MDedge Dermatology
No Routine Cancer Screening Option? New MCED Tests May Help
MDedge Dermatology
Most Targeted Cancer Drugs Lack Substantial Clinical Benefit
MDedge Dermatology
Keratoacanthoma, SCC Relatively Rare With PD-1/PD-L1 Inhibitors, Study Suggests
MDedge Dermatology
Few Cancer Survivors Meet ACS Nutrition, Exercise Guidelines
MDedge Dermatology
Chronic Cribriform Ulcerated Plaque on the Left Calf
MDedge Dermatology